This phase I trial is combining two anti-cancer drugs (Rucaparib and Atezolizumab) in patients with advanced cancers of the female reproductive system, ovarian cancer in particular.
This trial is treating patients with cancers of the female reproductive system, ovarian cancer in particular.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on Ovarian Cancer
This is a Phase Ib, open-label, non-randomized study in participants with advanced gynecological cancers (Part 1) and platinum-sensitive ovarian cancer (Part 2) to investigate the dose, safety, pharmacokinetics, and efficacy of rucaparib in combination with atezolizumab. The study is conducted in 2 parts: a Dose-Finding Phase (Part 1) and a Dose-Expansion Phase (Part 2).
Recruiting Hospitals Read More